Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chloroquine
Drug ID BADD_D00440
Description Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria.[A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine].[A191787] Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.[A192432] **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.[L14312]** Chloroquine was granted FDA Approval on 31 October 1949.[L12054]
Indications and Usage For the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis
Marketing Status Not Available
ATC Code P01BA01
DrugBank ID DB00608
KEGG ID D02366
MeSH ID D002738
PubChem ID 2719
TTD Drug ID D09EGZ
NDC Product Code Not Available
Synonyms Chloroquine | Chlorochin | Chingamin | Khingamin | Nivaquine | Chloroquine Sulfate | Sulfate, Chloroquine | Chloroquine Sulphate | Sulphate, Chloroquine | Aralen | Arequin | Arechine
Chemical Information
Molecular Formula C18H26ClN3
CAS Registry Number 54-05-7
SMILES CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Paranoia19.05.01.0050.000466%Not Available
Personality change19.05.01.006; 17.02.05.019--
Photosensitivity reaction23.03.09.003--
Pleural effusion22.05.02.0020.000699%
Pneumonia22.07.01.003; 11.01.09.0030.000466%Not Available
Polyneuropathy17.09.03.012--Not Available
Protrusion tongue17.02.05.037; 07.14.02.002--Not Available
Pruritus23.03.12.001--
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.000466%Not Available
Pulmonary arterial pressure increased13.14.03.0250.000466%Not Available
Pulmonary oedema22.01.03.003; 02.05.02.0030.000122%
Pulse pressure decreased13.14.04.0080.000466%Not Available
Pyrexia08.05.02.0030.000466%
Rash23.03.13.001--Not Available
Renal failure20.01.03.0050.000122%Not Available
Restrictive cardiomyopathy02.04.01.0050.001864%
Seizure17.12.03.0010.000932%
Skin exfoliation23.03.07.003--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Suicide attempt19.12.01.0040.000466%
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.000699%
Systemic lupus erythematosus15.06.02.003; 10.04.03.004; 23.03.02.0060.000466%Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Torticollis17.01.03.003; 15.05.04.003--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Urticaria10.01.06.001; 23.04.02.001--
Ventricular fibrillation02.03.04.0080.000243%
Ventricular hypertrophy02.04.02.0120.001631%Not Available
Vision blurred17.17.01.010; 06.02.06.007--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages